Published in Mol Cancer Ther on December 27, 2012
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol (2013) 0.98
Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell (2014) 0.95
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat (2015) 0.93
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. Int J Clin Exp Med (2015) 0.83
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev (2015) 0.81
Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics (2014) 0.77
The FGF/FGFR axis as a therapeutic target in breast cancer. Expert Rev Endocrinol Metab (2013) 0.77
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models. Neoplasia (2016) 0.75
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorg Med Chem (2016) 0.75
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models. Transl Oncol (2017) 0.75
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chin J Cancer (2016) 0.75
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol (2007) 3.38
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 2.27
Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol (2011) 2.21
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 1.98
Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res (2013) 1.80
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res (2005) 1.80
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev (2011) 1.63
Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor's proangiogenic microenvironment. Cell Mol Life Sci (2011) 1.62
Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol Cell (2012) 1.57
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol (2007) 1.54
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther (2009) 1.52
Translocation-related sarcomas. Semin Oncol (2009) 1.45
Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis. Eur Heart J (2005) 1.45
Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci (2002) 1.44
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle (2012) 1.44
Unleashing Chk1 in cancer therapy. Cell Cycle (2011) 1.44
Cherubism - new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg (2005) 1.43
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol (2005) 1.41
Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest (2007) 1.39
Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol Pharmacol (2004) 1.37
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.30
Model-based dissection of CD95 signaling dynamics reveals both a pro- and antiapoptotic role of c-FLIPL. J Cell Biol (2010) 1.30
Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 1.29
Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Res (2009) 1.29
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev (2013) 1.23
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle (2004) 1.22
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res (2004) 1.19
Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia (2008) 1.19
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res (2003) 1.19
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Gynecol Oncol (2011) 1.17
TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer (2010) 1.16
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics (2008) 1.14
Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol (2004) 1.12
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest (2002) 1.12
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res (2002) 1.09
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. Head Face Med (2008) 1.08
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol (2003) 1.08
Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood (2003) 1.07
Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line. Cancer Res (2005) 1.07
An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene (2004) 1.07
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther (2004) 1.05
TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. Eur J Cancer (2006) 1.04
Trabectedin therapy for sarcomas. Curr Opin Oncol (2010) 1.03
Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals. Biochem Biophys Res Commun (2003) 1.03
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle (2003) 1.03
Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics (2008) 1.03
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res (2008) 1.02
Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells. PLoS One (2010) 1.01
Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer (2007) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol (2009) 1.00
Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem Cell Biol (2012) 1.00
Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res (2008) 1.00
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). J Natl Cancer Inst Monogr (2011) 1.00
Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol (2003) 1.00
Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res (2008) 0.99
A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica (2006) 0.99
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol (2013) 0.98
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol (2010) 0.98
Unique features of the mode of action of ET-743. Oncologist (2002) 0.97
G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res (2008) 0.97
The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochem Pharmacol (2009) 0.97
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res (2003) 0.96
Two allele-specific PCR assays for screening epidermal growth factor receptor gene hotspot mutations in lung adenocarcinoma. Mol Med Rep (2011) 0.96
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res (2003) 0.95
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol (2007) 0.95